MRSA Clinical Trial
Official title:
Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
Intravenous vancomycin is considered first line therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections including bacteremia, central nervous system infection, pneumonia, pleural space infection, bone or joint infection, prosthetic joint infection and deep abscesses. The effectiveness and toxicity of vancomycin depend on its dosing and chosen target. The most recent guidelines suggest targeting area under the curve over 24 hours over minimum inhibitory concentration (AUC/MIC) of 400 to 600. Implementation of AUC/MIC requires Bayesian software that can be variable, costly, complicated and time consuming. Ideally, AUC/MIC dosing would also require susceptibility testing by broth microdilution, which is not commonly done. It is recommended to target AUC of 400 to 600 assuming a MIC of 1ug/mL when MIC by broth microdilution is not known. Targeting a trough level of 10 to 15mg/L may be a reasonable and more practical alternative without compromising effectiveness. We will be conducting a randomized controlled non-inferiority trial to compare intravenous vancomycin dosing strategy targeting a trough level of 10 to 15mg/L versus AUC of 400 to 600 assuming a MIC of 1ug/mL by broth microdilution for serious MRSA infections. The primary outcome will be treatment failure, which is a composite of mortality and microbiologic failure at 90 days. We hypothesize that targeting a trough level of 10 to 15mg/L is non-inferior to targeting a AUC of 400 to 600 in terms of treatment failure. The criterion for non-inferiority is that a two-sided 95% confidence interval for difference in risk of treatment failure will lie within the non-inferiority margin of 10%.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181932 -
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
|
Phase 3 | |
| Completed |
NCT03268122 -
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
|
N/A | |
| Completed |
NCT04312776 -
Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS
|
||
| Recruiting |
NCT04104178 -
Optimal Treatment of MRSA Throat Carriers
|
Phase 3 | |
| Completed |
NCT03601741 -
Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
|
N/A | |
| Completed |
NCT02690415 -
Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
|
||
| Enrolling by invitation |
NCT04297592 -
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
|
Phase 4 | |
| Recruiting |
NCT05268120 -
MRSA Decolonization in Complicated Carriage
|
N/A | |
| Completed |
NCT01167452 -
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
|
Phase 4 | |
| Recruiting |
NCT04083092 -
Surveillance of Community-Associated MRSA
|
||
| Recruiting |
NCT02443064 -
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
|
Phase 4 | |
| Completed |
NCT02029872 -
Stop Community MRSA Colonization Among Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05696132 -
Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients
|
Phase 2 | |
| Recruiting |
NCT02127658 -
MRSA Eradication and Decolonization in Children
|
N/A | |
| Completed |
NCT00822276 -
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
|
N/A | |
| Withdrawn |
NCT02547116 -
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
|
Phase 4 | |
| Completed |
NCT01318213 -
Benefits of Universal Glove and Gowning
|
||
| Completed |
NCT03304873 -
Retapamulin as a Decolonizing Agent for MRSA
|
Phase 3 | |
| Enrolling by invitation |
NCT05395520 -
Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?
|